On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly recommend that REGEN-COV (casirivimab with imdevimab) be used in non-hospitalized COVID-19 patients (“outpatients”) at high risk of clinical progression.